Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Zura Bio Limited Class A Ordinary Shares

ZURA

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Last trade $1.02
Day change -$0.065 (-6.02%)
Day range $0.986 – $1.08
Volume 2,811,879
Market cap $104M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$104.03M
Price / earnings
—
Price / book
0.59×
Price / sales
—
EV / sales
—
EV / EBITDA
0.82×

Profitability

Earnings per share
-$1.27
Return on assets
-62.8%
Return on equity
-68.8%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
11.29×
Quick ratio
11.29×
Cash ratio
11.06×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$22.35M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ZURA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$9.28M$8.62M$10.75M$7.46M$7.57M$9.36M$8.78M$6.49M
Research and development$19.49M$20.71M$14.75M$10.96M$11.95M$8.7M$10.47M$9.24M
Total operating expenses$28.77M$29.32M$25.5M$18.41M$19.52M$18.06M$19.25M$15.73M
Operating income-$28.77M-$29.32M-$25.5M-$18.41M-$19.52M-$18.06M-$19.25M-$15.73M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$27.05M-$26.39M-$24.22M-$17.18M-$18.04M-$15.99M-$17.44M-$13.63M
Income taxes-$1.22M-$81K$0$0$0$0$0$0
Net income-$25.83M-$26.3M-$24.22M-$17.18M-$18.04M-$15.99M-$17.44M-$13.63M
Net income attributable to common shareholders-$25.83M-$26.3M-$24.22M-$45.88M-$20.04M-$15.99M-$17.44M-$9.05M
EBITDA-$28.77M-$29.34M-$25.48M-$18.4M-$19.52M-$18.07M-$19.25M-$15.73M
Basic earnings per share-$0.20-$0.21-$0.22-$0.48-$0.21-$0.17-$0.19-$0.10
Diluted earnings per share-$0.20-$0.21-$0.22-$0.48-$0.21-$0.17-$0.19-$0.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering

JATT II Acquisition Corp, a blank check company focused on healthcare and biotechnology, successfully closed its $60 million IPO on April 20, 2026, offering 6 million shares at $10 per share on NASDAQ under ticker 'JATT'. The company, led by Dr. Someit Sidhu and sponsored by JATT Ventures II L.P., intends to pursue business combinations in healthcare and life sciences sectors with emphasis on data-driven therapeutic discovery approaches.

Zacks Investment Research

How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%

The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Zura Bio Limited (ZURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.